This hypothesis was plausible because 2 weeks' preoperative endocrine therapy had been shown to markedly reduce proliferation in human breast cancer as measured by Ki67.1, 2 Longstanding experimental evidence had shown that the stimulatory effect of surgery on the growth of metastases in mice could be inhibited by perioperative endocrine therapy.3, 4 Any improvement in long-term outcome following short exposure to preoperative or perioperative endocrine therapy would be achieved with no additional toxicity or resource implications and be of considerable clinical importance. Here, MKI67 is linked to breast carcinoma.